Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025

View source ↗

Summary

EMA's PRAC concluded the safety review of semaglutide medicines and started a safety review of two chickenpox vaccines.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• OZEMPIC (semaglutide)
• Rybelsus (semaglutide)
• WEGOVY (Semaglutide)

Snippet

EMA concludes review of semaglutide medicines and starts review of two chickenpox vaccines